Caruana E, et al. - In the MINDACT trial, researchers evaluated 1,497 females with early-stage breast cancer to determine the utility of the 70-gene signature via synthetic measure of quantity and quality of life (ie, the number of quality-adjusted life-years [QALYs]). All the women were observed with high clinical and low genomic risks. The investigators found 2.8% of 5-year disease-free survival gain; however, due to some related side effects, chemotherapy (CT) significantly decreased the number of QALYs by 62 days, conclusively documenting that 70-gene signature could be employed to avoid overtreatment by CT in females with high clinical risk but low genomic risk.